title: A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.
abstract: BACKGROUND
  Botulinum toxin is used to treat glabellar lines, but the optimal dose of Reloxin (Dysport, Ipsen Biopharm Ltd.) for this indication remains to be established.
  
  
  OBJECTIVE
  The objective was to evaluate three doses of Reloxin to determine its efficacy and safety in treating glabellar lines.
  
  
  METHODS
  Participants were given 20, 50, or 75 U of Reloxin, or placebo, injected across the glabella. Follow-up was on Days 7, 30, 60, 90, and 120. Adverse events were also elicited by telephone on Day 3.
  
  
  RESULTS
  From investigators' and participants' assessments at Day 30, there were significantly more responders in each Reloxin-treated group than placebo (p< or = 0.001). The 50-U dose was as effective as the 75-U dose, with a similar duration. The most common adverse events were mild headache and nasopharyngitis, occurring similarly in all groups.
  
  
  CONCLUSIONS
  Reloxin (Dysport/botulinum toxin type A) treatment resulted in a significant improvement in glabellar lines, and the 50-U dose was identified as optimal. All doses were well tolerated.
authors.affiliation: Department of Dermatology, University of Alabama Medical Center, Birmingham, Alabama 35205, USA. monheitgd421@pol.net
authors.forename: Gary
authors.initials: G
authors.lastname: Monheit
authors.forename: Alastair
authors.initials: A
authors.lastname: Carruthers
authors.forename: Fredric
authors.initials: F
authors.lastname: Brandt
authors.forename: Rhonda
authors.initials: R
authors.lastname: Rand
mesh_terms: D000328:Adult; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015595:Skin Aging / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A